Dr Rob Wallis
Rob is a pharmacologist by training with expertise in drug discovery and development. He has more than 30 years industry experience as head of Safety pharmacology at Pfizer with a world-wide reputation in the area of drug-induced QT prolongation/non-clinical cardiovascular safety. He has presented at many scientific conferences and at the FDA and is a member of the ICH E14 Q&A Technical Group. He is a former member of the Board of Directors of the Safety Pharmacology Society.